ClinicalTrials.gg

Program

HSK46256

A development code.

Its studies are led by Haisco Pharmaceutical Group.

Furthest: phase 1, since Jun 29, 20261 company-led study, 1 open or runningNext primary completion: Dec 30, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Haisco Pharmaceutical Group11 open or runningphase 1since Jun 29, 2026Jun 29, 2026Dec 30, 2028phase 1 · NCT07695142

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 29, 2026First study: phase 1 study in Advanced Solid Tumor (Phase 1)First studyNCT07695142 · 275 planned · China

Ahead

  1. Dec 30, 2028Primary completion: phase 1 study in Advanced Solid Tumor (Phase 1)NCT07695142

TargetBeta

PARP1 →read by rule
“This is a Phase 1, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of HSK46256 tablets, a selective PARP1 inhibitor, in patients with advanced solid tumors.”study text, by rule · the study

Other programs on PARP1

ProgramCompanyFurthest phaseStudies
olaparibruleAstraZenecaphase 478
niraparibruleGlaxoSmithKlinephase 443
saruparibruleAstraZenecaphase 314
senaparibruleimpact-therapeutics-incphase 212
nesuparibruleJeil Pharmaceuticalphase 24
palacaparibAstraZenecaphase 23
PARP1 Inhibitor HS-10502ruleHansoh Pharmaceutical Groupphase 12
DM5167ruledigmbiophase 11
TQB3122Sino Biopharmaceuticalphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07695142Advanced Solid Tumor (Phase 1) · China1RecruitingDec 30, 2028275

How it is read

Names in the registry

  • “HSK46256”, 1 entry

Codes read as this program: HSK46256.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.